• Mar 10, 2025

3 Reasons LESL is Risky and 1 Stock to Buy Instead

Leslie's has gotten torched over the last six months - since September 2024, its stock price has dropped 64.2% to $1.05 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

  • Mar 10, 2025

3 Reasons to Sell DBD and 1 Stock to Buy Instead

Diebold Nixdorf has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 7.8% to $43.96 per share while the index has gained 3.8%.

  • Mar 10, 2025

3 Reasons SITE is Risky and 1 Stock to Buy Instead

Since September 2024, SiteOne has been in a holding pattern, posting a small loss of 3.9% while floating around $127.85. The stock also fell short of the S&P 500’s 3.8% gain during that period.

  • Mar 10, 2025

3 Reasons PFE is Risky and 1 Stock to Buy Instead

Over the past six months, Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain. This might have investors contemplating their next move.

  • Mar 10, 2025

3 Reasons to Sell DVA and 1 Stock to Buy Instead

Since September 2024, DaVita has been in a holding pattern, posting a small loss of 4.3% while floating around $147.02. The stock also fell short of the S&P 500’s 3.7% gain during that period.